State mandates are a straightforward way to avert the negative consequence of federal mandate repeal at the state level, according to the latest analysis out of the USC-Brookings Schaeffer Initiative.
Matthew Fielder examines how premiums would change in 2019 absent recent policy changes that are set to take effect.
Mark Hall examines the causes of instability in the individual market and identifies measures to help improve stability based off of interviews with key stakeholders in 10 states.
Matthew Fiedler presents evidence that the ACA’s individual mandate did indeed cause substantial increases in insurance coverage.
John Romley and Paul Ginsburg look at three ways to improve the effectiveness of bundled payment systems.
A state-level financing strategy could help Medicaid programs provide access to hepatitis C patients while still encouraging future pharmaceutical innovation.
Schaeffer Initiative researchers propose two key changes to the MA bidding process to lower prices and enhance choice for consumers.
In 2013, almost one quarter of filled pharmacy prescriptions (23%) involved a patient copayment that exceeded the average reimbursement paid by the insurer by more than $2.00.
The researchers examined copay coupon availability for the top 200 drugs (by spending) in 2014. Of these, 132 were brand drugs, and 90 of those had coupons available.
Calculations using publicly available aggregate data suggest that the United States market accounts for 64 to 78 percent of worldwide pharmaceutical profits.